^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2-Negative and postmenopausal or premenopausal receiving ovarian ablation or suppression: Preferred Regimens: Second and subsequent line therapy: Everolimus + endocrine therapy (exemestane, fulvestrant, tamoxifen).
    Secondary therapy:
    fulvestrant; exemestane; tamoxifen
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

    Excerpt:
    ...- Postmenopausal advanced hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer after failure of treatment with letrozole or anastrozole...
    Trial ID:
    NCT02273752
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

    Excerpt:
    ...- Metastatic breast cancer HR+ (Hormone Receptor positive), HER2/neu negative (Human Epidermal Growth Factor Receptor-2)...
    Trial ID:
    RAPANK
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A randomized controlled trial for Neoadjuvant Everolimus Plus EC followed by T Compared With EC followed by T in patients with ER-positive, HER2-negative operable breast cancer

    Excerpt:
    ...No distant metastasis by histological diagnosis of histological grade level III of invasive breast cancer patients (T > 2 cm, or any T and histological diagnosis of metastatic axillary lymph node > 2 cm), tumor molecular diagnosis of ER positive immunohistochemical study (ER positive percentage of 10% or higher), her2-negative (HER2 immunohistochemical staining 0 or 1 + or fluorescence in situ hybridization FISH -); 3. ...
    Trial ID:
    ChiCTR1900021070
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

    Excerpt:
    ......
    Trial ID:
    UNIRAD
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

    Excerpt:
    ...HER2 is negative if a single test (or all tests) performed in a tumor specimen show: 1....
    Trial ID:
    NCT01674140
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

    Excerpt:
    ...Histological or cytological confirmation of estrogen-receptor positive (ER+), HER2 negative breast cancer....
    Trial ID:
    PEARL
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

    Excerpt:
    ...- Patients must have a histologically confirmed diagnosis of hormone receptor positive, HER2 negative invasive breast carcinoma....
    Trial ID:
    NCT02236572
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

    Excerpt:
    ......
    Trial ID:
    NCT05054166
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus

    Excerpt:
    ...- Patients affected of a breast cancer advanced andor metastatic HER2 negative expressing the hormonal receptor RH +...
    Trial ID:
    EVERIMMUN
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

    Excerpt:
    ...HER2-negative breast cancer, defined as follows:...
    Trial ID:
    NCT02291913
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Everolimus TDM to Predict Long Term Toxicity

    Excerpt:
    ...- Patients currently treated with everolimus for any type of cancer, such as the EMA registered indications i.e. advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer, metastatic renal cell carcinoma (mRCC) or neuroendocrine tumour (NET) of pancreatic, gastrointestinal or lung origin....
    Trial ID:
    Foresight